Diagnosing Immune Thrombocytopenia.
Sachs UJ.
Hamostaseologie. 2019 Aug;39(3):250-258. doi: 10.1055/s-0039-1678739. Epub 2019 Feb 14.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group.
Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ.
Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group.
Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28.
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C, Cheng Y.
J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8.
Roxithromycin-Associated Acute Thrombocytopenia.
Rossi M, Capecchi M, Lazzerini PE.
Am J Case Rep. 2021 Jun 30;22:e932039. doi: 10.12659/AJCR.932039.
Mean platelet size related to glycoprotein-specific autoantibodies and platelet-associated IgG.
Javela K, Kekomäki R.
Int J Lab Hematol. 2007 Dec;29(6):433-41. doi: 10.1111/j.1751-553X.2007.00885.x.
Flow cytometric detection of platelet-associated immunoglobulin in patients with immune thrombocytopenic purpura and nonimmune thrombocytopenia.
Huh HJ, Park CJ, Kim SW, Han SH, Jang S, Chi HS.
Ann Clin Lab Sci. 2009 Summer;39(3):283-8.
Comparison of ABO antibody titration, IgG subclasses and qualitative haemolysin test to reduce the risk of passive haemolysis associated with platelet transfusion.
Bastos EP, Castilho L, Bub CB, Kutner JM.
Transfus Med. 2020 Aug;30(4):317-323. doi: 10.1111/tme.12687. Epub 2020 Jun 2.
Platelet associated IgG, platelet mean life span and treatment with intravenous immunoglobulin in idiopathic thrombocytopenic purpura.
Nieminen U, Syrjälä M, Ikkala E, Myllylä G.
Eur J Haematol. 1988 Apr;40(4):326-31. doi: 10.1111/j.1600-0609.1988.tb00186.x.
